Previous 10 | Next 10 |
2024-02-13 11:26:18 ET More on AN2 Therapeutics Biggest stock movers today: Diamondback Energy, Joby Aviation, monday.com, and more AN2 Therapeutics plunges after pause on pivotal trial Seeking Alpha’s Quant Rating on AN2 Therapeutics Historical earnin...
A look at the top 10 most actives in the United States Beamr Imaging Ltd. (BMR) rose 371.6% to $9.95 on volume of 154,937,988 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 0.7% to $4.34 on volume of 137,498,905 shares Arm Holdings plc (ARM) rose 29.3% to $148.97 on volume...
A look at the top 10 most actives in the United States Beamr Imaging Ltd. (BMR) rose 687.2% to $16.61 on volume of 140,756,692 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 0.0% to $4.3084 on volume of 120,282,414 shares Arm Holdings plc (ARM) rose 26.0% to $145.1201 on v...
BOSTON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating AN2 Therapeutics, Inc. (NASDAQ: ANTX) for potential securities law violations. Investors who have lost money in their AN2 Therapeutics, Inc. investment should contact the firm to learn more about how they might rec...
2024-02-12 10:00:07 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Lilly, Zoetis, Abbott least shor...
2024-02-12 08:27:22 ET More on Pre-market losers & stocks. Manchester United: Public Market Discount Manchester United: A Historic Giant Facing Valuation Challenges And Why It's Time To Sell Knives Are Out For Vuzix Corporation Manchester United appoints ...
2024-02-12 07:52:37 ET More on AN2 Therapeutics Seeking Alpha’s Quant Rating on AN2 Therapeutics Historical earnings data for AN2 Therapeutics Financial information for AN2 Therapeutics Read the full article on Seeking Alpha For further details...
-Enrolled patients allowed to continue on study- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the company’s decision to ...
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO will present at the Oppenheimer 34 th Ann...
2024-01-06 02:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
AN2 Therapeutics Inc. Company Name:
ANTX Stock Symbol:
NYSE Market:
2024-04-02 05:30:04 ET JMP Securities analyst issues OUTPERFORM recommendation for ANTX on April 2, 2024 02:23AM ET. ANTX was trading at $3.76 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recom...
Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during continued analysis of incoming data; plan to discuss with FDA Cash, cash equivalents, and inve...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...